We have proposed to test the efficacy of combination therapy of a progesterone receptor (PR) modulator ulipristal acetate (UPA) and a selective COX-2 inhibitor (Celecoxib) for prevention of Brca1 deficient mammary tumorigenesis in a mouse model. In this 2nd year, we will continue on this theme. We have actively cross-bred to build the experimental cohort with Ad-K8-Cre Brca1f22-24/f22-24; Trp53f2-10/f2-10; R26Y mice (named as BPY mice) to test drug efficacy and expect randomization to the treatment in August.
|Effective start/end date||10/1/21 → 9/30/22|
- Breast Cancer Research Foundation (BCRF-21-087)
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.